The role of GABA transport proteins, or GAT proteins, have sparked interest as targets for antiepileptic drugs. The FDA approved drug Tiagabine has shown selective and potent inhibition of the GAT 1 protein. With the use of several different starting compounds (2-, 3-, and 4-nitrobenzenesulfonyl chloride) we are aiming to synthesize cyclic sulfonimamides that may show effective inhibition at one or more isotype of the GAT proteins, in particular interest is the GAT-2, GAT-3, and BGT-1 proteins as there are currently no selective and potent inhibitors of these proteins at this point in time.

Potential use of cyclic sulfonimidamides in the inhibition of non GAT-1 proteins

246th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.